Skip to main content
. 2023 Jul 24;14:1080188. doi: 10.3389/fendo.2023.1080188

Table 2.

Folic acid levels in patients with arteriogenic ED, grouped by PSV range.

Arteriogenic ED (N=74) P
PSV <20cm/s (N=20) PSV 20–30cm/s (N=39) PSV 30–35cm/s (N=15)
Age, years 37.15 ± 11.74 36.18 ± 8.20 39.47 ± 9.86 0.532 a
BMI, kg/m2 25.24 ± 2.37 24.59 ± 2.30 24.29 ± 2.12 0.433 a
FBG, mmol/L 4.53 ± 0.59 4.85 ± 0.62 4.64 ± 0.77 0.193 a
TC, mmol/L 4.53 ± 1.52 4.41 ± 1.17 4.29 ± 1.22 0.722 a
TG, mmol/L 1.73 ± 0.75 1.55 ± 0.60 1.46 ± 0.71 0.466 a
Total T, nmol/L 20.63 ± 4.35 20.70 ± 3.87 21.64 ± 3.78 0.702 a
FA, ng/ml 5.97 ± 1.51 8.21 ± 2.37 10.55 ± 2.56 <0.001a
IIEF-5 score 7.5 (5.25-9.75) 12 (10-14) 18 (17-20) <0.001b
PSV, cm/s 15.75 ± 2.39 23.53 ± 2.19 32.72 ± 1.64 <0.001a

ED, erectile dysfunction; BMI, body mass index; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; Total T, total testosterone; FA, folic acid; IIEF-5, International Index of Erectile Function-5; PDU, penile Doppler ultrasonography; PSV, peak systolic velocity; EDV, end-diastolic velocity; RI, resistive index.

a statistically significant difference as indicated by one-way ANOVA; b statistically significant difference as indicated by Kruskal–Wallis H test.

The bold values means that there were significant difference between the three group on the compared characteristics.